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Characterization of a model of 
systemic inflammation in humans 
in vivo elicited by continuous 
infusion of endotoxin
D. Kiers1,2,*, R. M. Koch1,2,*, L. Hamers1,2, J. Gerretsen1,2, E. J. M. Thijs1, L. van Ede1, 
N. P. Riksen3, M. Kox1,2 & P. Pickkers1,2
Investigating the systemic inflammatory response in patients with critical illness such as sepsis, trauma 
and burns is complicated due to uncertainties about the onset, duration and severity of the insult. 
Therefore, in vivo models of inflammation are essential to study the pathophysiology and to evaluate 
immunomodulatory therapies. Intravenous bolus administration of endotoxin to healthy volunteers is 
a well-established model of a short-lived systemic inflammatory response, characterized by increased 
plasma cytokine levels, flu-like symptoms and fever. In contrast, patients suffering from systemic 
inflammation are often exposed to inflammatory stimuli for an extended period of time. Therefore, 
continuous infusion of endotoxin may better reflect the kinetics of the inflammatory response 
encountered in these patients. Herein, we characterize a novel model of systemic inflammation elicited 
by a bolus infusion of 1 ng/kg, followed by a 3hr continuous infusion of 1 ng/kg/h of endotoxin in healthy 
volunteers, and compared it with models of bolus administrations of 1 and 2 ng/kg of endotoxin. 
The novel model was well-tolerated and resulted in a more pronounced increase in plasma cytokine 
levels with different kinetics and more prolonged symptoms and fever compared with the bolus-only 
models. Therefore, the continuous endotoxin infusion model provides novel insights into kinetics of 
the inflammatory response during continuous inflammatory stimuli and accommodates a larger time 
window to evaluate immunomodulating therapies.
Systemic inflammation is a common hallmark of patients with sepsis1, trauma2, burns3, as well as those undergo-
ing major surgery4. This inflammatory response follows the activation of specific receptors by pathogen-, or dan-
ger associated molecular patterns (PAMPs and DAMPs), and is characterized by the production of cytokines and 
chemokines. In turn, these cytokines and chemokines trigger complement activation and coagulation, leukocyte 
migration, and increased vascular permeability5. A dysregulated immune response can have detrimental effects, 
such as hemodynamic instability, organ dysfunction, and prolonged immune suppression6.
A comprehensive appreciation of the innate immune response is crucial to understand the pathogenesis of 
systemic inflammation observed in patients. However, investigating the innate immune response in patients is 
hampered by heterogeneity, uncertainties about the moment of onset and, in the case of sepsis, the accuracy of 
the diagnosis6. In order to overcome these impediments, models of systemic inflammation may facilitate investi-
gations into the pathophysiological mechanisms and evaluate the effects of immunomodulatory interventions. As 
in vitro and animal models have obvious drawbacks concerning extrapolation to humans7, investigating systemic 
inflammation and immunomodulation is of great importance8.
A controlled, transient and reproducible systemic inflammatory response in humans can be achieved 
with an intravenous (i.v.) bolus administration of endotoxin (lipopolysaccharide (LPS)), a compound derived 
from the cell membrane of Gram-negative bacteria. This inflammation is characterized by flu-like symptoms, 
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fever, hemodynamic alterations and increased plasma levels of cytokines9. Previous studies have shown a 
dose-dependent effect of endotoxin on the magnitude of the inflammatory response, but largely unaltered kinet-
ics with increasing endotoxin dosages10–12. Furthermore, repeated endotoxin administration studies have 
demonstrated the development of endotoxin tolerance, representing an immune suppressed state that resembles 
sepsis-induced immunoparalysis13. This experimental human endotoxemia model has been frequently used to 
investigate the pathophysiology of systemic inflammation, to assess a broad range of immunosuppressive and 
immunostimulatory drugs and non-pharmacological interventions14–17, and to evaluate the effects of inflamma-
tion on other biologic processes, such as iron homeostasis18.
Patients suffering from systemic inflammation are in most cases exposed to inflammatory stimuli for extended 
periods of time19. Therefore, a bolus administration of endotoxin likely poorly reflects the kinetics of the inflam-
matory response observed in these patients9,19, and a continuous infusion of endotoxin may provide a more 
accurate representation. Furthermore, as the endotoxin-induced inflammatory response is rapidly orchestrated 
and waned after bolus administration, investigational treatments are typically initiated before endotoxin admin-
istration. Although this approach increases the likelihood to show efficacy of the intervention in the experimental 
model, it does not reflect the clinical situation in which treatment is initiated after systemic inflammation has pre-
sented. An inflammatory model that develops over several hours may provide a larger time window to evaluate 
interventions once inflammation has developed.
Taken together, the pathophysiology of systemic inflammation and immunomodulatory treatments are dif-
ficult to study in patients. The human endotoxemia model that is currently used is characterized by a rapid and 
short-lived systemic inflammatory response after a bolus administration of endotoxin. A continuous infusion 
of endotoxin may provide more insight into the kinetics of the inflammatory response in patients with ongoing 
inflammation.
Herein, we characterize a novel model of systemic inflammation elicited by continuous endotoxin infusion 
(an initial endotoxin bolus of 1 ng/kg followed by 1 ng/kg/h for 3 hours). Additionally, we provide a context to 
interpret the characteristics of the continuous infusion model by describing the characteristics of endotoxin mod-
els using 1 or 2 ng/kg bolus administrations and responses to placebo administration. We report the kinetics 
of plasma cytokines, hemodynamic alterations, symptoms and leukocyte changes, and explore the coherence 
between different cytokines and their association with clinical parameters.
Results
Demographic characteristics, elicitation of systemic inflammation and safety. Eligible subjects 
were healthy, non-smoking male subjects, aged 18–35 years. Demographic characteristics of the subjects are listed 
in Table 1. All subjects were Caucasian. There were no differences in baseline characteristics between the groups. 
All subjects received a venous and arterial cannula to accommodate infusion of fluids and endotoxin and frequent 
blood withdrawal and continuous blood pressure monitoring. Systemic inflammation was elicited by either con-
tinuous endotoxin infusion (an initial endotoxin bolus of 1 ng/kg, followed by 1 ng/kg/h for 3 hours) or a bolus 
administration of 1 or 2 ng/kg bolus administrations of endotoxin. The placebo group received a comparable 
volume of NaCl 0.9%. No serious adverse events occurred and all subjects were well at the time of discharge, eight 
hours after initiation of endotoxin administration.
Plasma cytokines and chemokines. To determine serial plasma levels of cytokines Tumor Necrosis 
Factor (TNF)-α , interleukin (IL)-1β , IL-6 and IL-10 (Fig. 1) and chemokines (C-X-C-motif) ligand (CXCL)8 
(also known as IL-8), Monocyte Chemoattractant Protein (MCP)-1, Macrophage Inflammatory Protein 
(MIP)-1α and MIP-1β , blood was frequently sampled throughout the experiment. All plasma cytokine concen-
trations were below detection limits in all subjects prior to endotoxin administration and significantly increased 
afterwards (Fig. 2). In the placebo group, no increases in any of the cytokines and chemokines were observed.
Kinetics of plasma cytokines and chemokines. In the continuous infusion group, the kinetics of all cytokines and 
chemokines were markedly different compared with bolus administration of 2 ng/kg (Figs 1 and 2). Of note, in 
the continuous infusion group plasma levels of TNF-α and MIP-1α already decreased before endotoxin infusion 
was stopped. The differences between 1 and 2 ng/kg bolus administration groups were less pronounced, and only 
reached statistical significance for TNF-α , IL-1β , IL-10 and MIP-1α .
Total cytokine and chemokines production. The total cytokine response, expressed as the area under the 
time-concentration curve (AUC), was higher for IL-1β , IL-6, IL-10, MCP-1 and MIP-1α in the continuous 
placebo
n = 15
bolus
1 ng/kg n = 10
bolus
2 ng/kg n = 15
bolus
1 ng/kg + continuous 3 ng/kg n = 10 p-value
Age [yrs] 21.5 ± 0.5 21.1 ± 0.9 21.7 ± 0.7 23.6 ± 1.6 0.30
Height [cm] 181 ± 2 185 ± 2 185 ± 2 182 ± 2 0.40
Weight [kg] 77 ± 3 78 ± 3 78 ± 3 77 ± 4 0.98
BMI [kg/m2] 23.4 ± 0.9 22.8 ± 0.7 23.0 ± 0.8 23.2 ± 0.7 0.96
Table 1.  Demographic characteristics of subjects. Data were obtained during screening visit and are 
presented as mean ± SEM. P-values were calculated using one-way ANOVAs. yrs: years, cm: centimeter, kg: 
kilogram, BMI: body mass index, m: meter.
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infusion group compared with the 2 ng/kg bolus group, but similar for TNF-α and CXCL8. There was a trend 
towards higher total production of MIP-1β in the continuous infusion group. Except for higher production of 
IL-10 in the 2 ng/kg bolus administration group, there were no differences in total cytokine production between 
the 1 and 2 ng/kg bolus groups.
Clinical parameters. Endotoxin-induced flu-like symptoms (headache, nausea, shivering, muscle and back 
pain) reported by the subjects were scored every 30 minutes at 0–5 points. These symptoms remained at baseline 
in placebo-treated subjects, whereas the onset of flu-like symptoms was observed one hour after initiating endo-
toxin administration (Fig. 3). Continuous endotoxin infusion resulted in prolonged, but equally severe, flu-like 
symptoms in comparison to 2 ng/kg bolus administration. Small differences in the kinetics of the symptom scores 
were identified between the 1 and 2 ng/kg bolus administration groups. However, the total burden of symptoms, 
represented by the area under the time-symptom curve, was identical in these groups. The rise in temperature 
was markedly more pronounced in the continuous administration group compared with the 2 ng/kg bolus group, 
whereas there were no differences in the temperature response between the 1 and 2 ng/kg bolus administration 
groups (Fig. 3). Although an endotoxin-dose-dependent increase in heart rate was observed, mean arterial pres-
sure decreased to a similar extent in all subjects, also in those who received placebo (Fig. 3).
Hematological parameters. Endotoxemia resulted in neutrophilia, and a mono- and lymphocytopenia, 
with the nadir at two and four hours, respectively (Fig. 4). These hematologic changes were more pronounced 
in the continuous infusion group compared with bolus administration of 2 ng/kg endotoxin. Neutrophilia was 
Figure 1. Kinetics and total production of cytokines. In the left panels, plasma concentrations of Tumor 
Necrosis Factor (TNF)-α , Interleukin(IL)-1β , IL-6 and IL-10 over time are depicted. The arrow represents 
the time of bolus endotoxin administration, the grey bar represents the period of endotoxin infusion in the 
continuous endotoxin group. Data are expressed as mean ± SEM pg/mL. Differences between groups were 
evaluated using 2-way ANOVAs (of time × group), and interaction term p-values are displayed. In the right 
panels, dot plots of the area under the time-concentration curve (AUC) with mean ± SEM are shown. Differences 
between groups were evaluated using Students t-tests. *p < 0.05, **p < 0.01, *p < 0.0001, #p = 0.05–0.10.
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similar after a endotoxin bolus of 1 and 2 ng/kg, while the kinetics of circulating monocyte and lymphocyte num-
bers differed slightly, yet significantly.
Hierarchical clustering and exploratory factor analysis. To identify relationships and similarities 
between cytokines and subjects, we performed hierarchical clustering analysis on cytokine responses and subjects. 
This analysis revealed a separate cluster for the anti-inflammatory cytokine IL-10, while three clusters were iden-
tified consisting of CXCL8, TNF-α and MCP-1, MIP-1α and MIP-1β , and IL-6 and IL-1β (Fig. 5). Subjects clus-
tered into three distinct groups; those who received continuous infusion (middle rows), those with low cytokine 
responses (upper rows) after bolus administration, and those with high cytokine responses (lower rows) after 
bolus administration. To explore to what extent cytokines responses are related, we performed exploratory factor 
analyses. This is an unsupervised method that can identify latent constructs (factors) in a multi-dimensional data 
set. The loading of a variable on a factor represents the relative weight of the variable in the factor. Exploratory 
factor analyses revealed similar grouping of cytokines (Table 2); with high loadings of CXCL8 and TNF-α in fac-
tor 1, a high loading of IL-10 in factor 2, a high negative loading of IL-1β and IL-6 in factor 3, and high loadings 
of MIP-1α and MIP-1β in factor 4. These factors explain 92% of the variance in the dataset. Factor 3, which has 
high negative loadings of IL-1β and IL-6, correlated with symptoms and change in temperature (Fig. 6). As such, 
high values of IL-1β and IL-6 are associated with higher symptom severity and a larger increase in temperature. 
Change in heart rate correlated with factor 2, which has a high loading of IL-10.
Figure 2. Kinetics and total production of chemokines. In the left panels, plasma concentration of CXC 
motif ligand (CXCL) 8, Monocyte Chemoattractant Protein (MCP) and Macrophage Inflammatory Protein 
(MIP)-1α and 1β over time are depicted. The arrow represents the time of bolus endotoxin administration, the 
grey bar represents the period of endotoxin infusion in the continuous endotoxin group. Data are expressed as 
mean ± SEM pg/mL. Differences between groups were evaluated using 2-way ANOVAs (of time × group), and 
interaction term p-values are displayed. In the right panels, dot plots of the area under the time-concentration 
curve (AUC) with mean ± SEM are shown. Differences between groups were evaluated using with Students 
t-tests. *p < 0.05, **p < 0.01, *p < 0.0001.
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Discussion
Herein, we characterize a novel human in vivo model of systemic inflammation elicited by continuous endotoxin 
infusion. Furthermore, we provide a framework for interpretation of this model by also describing two models 
of systemic inflammation elicited by bolus administration of endotoxin. This novel model of continuous infusion 
resulted in a higher production of IL-6, IL-10, MCP-1 and MIP-1α , and different kinetics of all cytokines as well 
as circulating leukocyte numbers. Furthermore, it resulted in a more pronounced rise in temperature and heart 
rate, and prolonged duration of flu-like symptoms. As such, this novel model induces a more pronounced and 
sustained systemic inflammatory response. There were no relevant differences in cytokine responses, clinical 
parameters, and leukocyte kinetics between bolus administrations of 1 or 2 ng/kg endotoxin. In addition, unsu-
pervised clustering and exploratory factor analysis revealed identical clusters of cytokines, some of which are 
clearly associated with clinical symptoms and fever.
We are the first to describe a model of continuous infusion of endotoxin at a relatively high dose of 1 ng/
kg/h. Low dose endotoxin infusion of another E coli derived batch ( G2 B274, 0.075 ng/kg/h) has been described 
previously20. At this lower dose, endotoxin infusion increased body temperature with 0.5 ᵒ C, and cytokine levels 
peaked to 5–10 and 20–70 pg/mL for TNF-α and IL-6, respectively20. These changes are far more discrete com-
pared with the higher dose continuous infusion model reported here, in which body temperature rises with 2.5 ᵒ  C 
and peak levels of TNFα and IL-6 are 340 pg/ml and 1000 pg/mL respectively. As such, low dose infusion mimics 
low-grade inflammation, as observed in chronic illnesses such as metabolic syndrome, atherosclerosis and type 
Figure 3. Kinetics and area under the curve of clinical parameters. In the left panel, change over time of 
symptoms (arbitrary units), temperature (°C), heart rate (beats per minute (bpm)), and mean arterial pressure 
(MAP) (mmHg) over time are depicted. The arrow represents the time of bolus endotoxin administration, the 
grey bar represents the period of endotoxin infusion in the continuous endotoxin group. Data are expressed 
as mean ± SEM. Differences between groups were evaluated using 2-way ANOVAs (of time × group), and 
interaction term p-values are displayed. In the right panel, dot plots of the area under the time-concentration 
curve (AUC) with mean ± SEM are shown. The AUC of temperature, heart rate and MAP was corrected 
for baseline. Differences between groups were evaluated using with Students t-tests. *p < 0.05, **p < 0.01, 
*p < 0.0001.
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2 diabetes20, whereas high dose infusion results in more profound systemic inflammation as observed in patients 
with sepsis. The cumulative dose of 4 ng/kg of endotoxin has been administered safely as a bolus in previous 
studies10–12. Therefore, no safety issues were expected, and indeed no serious adverse events occurred.
Previous studies have evaluated the dose-effects of different batches of endotoxin, in bolus administrations 
ranging from 0.5 ng/kg to 4 ng/kg10–12. These studies have shown that the extent of inflammation elicited by endo-
toxin administration is dose-dependent, but the difference between successive dosages may be too small to be 
significant. Similarly, we did not observe a clear dose-dependent effect concerning the 1 and 2 ng/kg endotoxin 
bolus administrations, although this was not the primary goal of this study. For most cytokines, the total response 
in the continuous model was higher compared to the 2 ng/kg bolus model. Although our study design does not 
allow to differentiate whether this is due to dose or infusion mode, these data indicate a more profound systemic 
inflammatory response using the continuous infusion protocol. However, in this context it is noteworthy that the 
total production of TNF-α and CXCL8 remained similar to that observed after bolus administration of 2 ng/kg 
Figure 4. Time course of leukocytes. Bars represent mean ± SEM of circulating numbers of neutrophils, 
monocytes and lymphocytes. Differences between groups were evaluated using 2-way ANOVAs (time × group), 
and interaction term p-values are displayed.
Figure 5. Hierarchial clustering of cytokines and chemokines and subjects. Each subjects occupies a row and 
each cytokine or chemokines occupies a column. The color code shows the normalized, log-transformed plasma 
concentration below (blue) or above (red) the mean, or at the median (black). The vertical axis on the left shows 
the color code of each subject classified as 1 ng/kg (light grey), 2 ng/kg (dark grey) or continuous infusion 
(black).
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endotoxin. TNF-α is known as the primary mediator in the inflammatory response and CXCL8 attracts and acti-
vates leukocytes to the site of infection21. Speculatively, both TNF-α and CXCL8 are under the control of a nega-
tive feedback mechanism that prevents unrestrained triggering of the inflammatory cascade, thereby prohibiting 
an uncontrolled pro-inflammatory response. This theory is supported by the observation that in the continuous 
endotoxin infusion group, plasma levels of TNF-α are already declining while endotoxin infusion continues. 
This phenomenon is also observed in patients with sepsis, in whom plasma levels of TNF-α decline rapidly and 
therefore do not represent disease severity22. In contrast to the restrained production of TNF-α and CXCL8, we 
observed a fourfold increase in IL-10 and IL-6 during continuous endotoxin infusion in comparison to bolus 
administration. IL-10 is the archetypal anti-inflammatory cytokine which inhibits the production of TNF-α 
and IL-1β . IL-6 exerts both pro- and anti-inflammatory effects, as it not only activates B- and T-lymphocytes 
and triggers the acute phase response and the coagulation cascade, but also can inhibit production of TNF-α 21. 
Therefore, the distinct surge in IL-10 and IL-6 levels may be part of the negative feedback mechanism that con-
trols TNF-α and CXCL8. Understanding the orchestration of the pro- and anti-inflammatory balance is of great 
interest, as a shift towards anti-inflammation is observed in patients with ongoing systemic inflammation23. This 
shift is presumed to prevent collateral damage of the pro-inflammatory response, but can also result in loss of 
Factor 1 Factor 2 Factor 3 Factor 4
% of variance 
explained 64.5% 10.9% 9.2% 7.5%
CXCL8 0.999
TNF-α 0.805 0.189
MCP-1 0.472 0.213 − 0.255 0.256
IL-10 1.010
IL-1β − 1.008
IL-6 0.243 0.262 − 0.688
MIP-1β 0.989
MIP-1β 0.302 0.730
Table 2.  Exploratory factor analysis pattern matrix. Pattern matrix after oblimin rotation with Kaiser 
Normalisation as obtained from EFA on log-transformed normalized area’s under time-concentration curves of 
cytokines after endotoxin administration. Only loadings > 0.1 are displayed.
Figure 6. Correlations of factors with clinical parameters. Correlations between individual score on Factor 
3 and the area under the curve (AUC), Factor 3 and symptoms (Panel A) and the baseline-corrected AUC of 
temperature (Panel B) and Factor 2 and the baseline-corrected AUC of heart rate (Panel C). R and p-values were 
calculated using Pearson correlations.
www.nature.com/scientificreports/
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immunocompetence and subsequently increase susceptibility to secondary infections. In sepsis patients, this 
phenomenon is termed sepsis-induced immunoparalysis24, although it is also observed in patients following 
trauma25 and cardiac resuscitation26 within hours after the insult. Therefore, the disproportionate production of 
anti-inflammatory cytokines during continuous infusion may mirror inflammation-induced immunoparalysis 
observed in patients.
Two independent, unsupervised clustering methods yielded similar groups of cytokines. Although these anal-
yses uncover the relationships between cytokines, they do not provide a theoretical framework to explain these 
relationships and need to be interpreted with caution. Nevertheless, some notable relationships are observed. 
First, the primordial anti-inflammatory cytokine IL-10 has its own cluster, which explains 10% of the variance of 
the data Second, the aforementioned pro-inflammatory cytokine TNF-α and the chemokine CXCL8 are closely 
linked. The third group consists of IL-1β and IL-6, which are both potent pyrogens. The last group consists of 
MIP-1α and MIP-1β , both chemokines produced by macrophages, which attract and activate granulocytes and 
stimulate the production of other cytokines. Perhaps not surprisingly, component 3, with pyrogens IL-6 and IL-1β 
correlates significantly with the development of fever and symptoms. A direct correlation between the level of 
cytokines and clinical outcomes was previously unidentified10. It appears plausible that, using exploratory factor 
analysis, we have increased the power to identify meaningful correlations by quantifying the response of each 
individual on factors, which are groups of cytokines that act alike, instead of the cytokines by themselves.
Endotoxemia models have limitations. First, endotoxemia is an experimental model of inflammation, which 
only embodies certain aspects of the pathophysiology of sepsis, trauma, burns, and major surgery. However, as 
these conditions are heterogeneous by themselves, their pathogenesis is difficult to study in patients. Therefore, 
endotoxemia models should be envisioned as a complementary method to study the pathophysiology of systemic 
inflammation, in addition to in vitro, ex vivo and animal studies, and clinical studies in patients. Second, we did not 
identify relevant changes in mean arterial blood pressure in comparison to the placebo group. This is in contrast 
to the findings of a previous study in which a bolus administration of 4 ng/kg EC-5 endotoxin resulted in a pro-
found hyperdynamic state with depressed left ventricular ejection fraction and reduced myocardial contractility27. 
Perhaps a bolus administration of 4 ng/kg, instead of a gradual infusion is required to produce such effects. The 
herein described models should therefore be used with apprehension to study hemodynamic changes in patients 
with systemic inflammation, and other models of sepsis may be more suitable for this purpose. We have not 
included a group in which a bolus injection of 4 ng/kg was administered to identify if differences between bolus 
and continuous infusion are the resultant of differences in dose or infusion rate. This limits the interpretation as 
to what extent the differences between the models are caused by dose or infusion mode.
The human model of systemic inflammation evoked by continuous infusion of endotoxin as described in the 
present study provides several new research opportunities. In bolus models, the inflammatory response comes 
and goes rapidly, limiting the possibility to demonstrate an effect of an intervention initiated following endotoxin 
administration. With continuous infusion, inflammation develops more gradually and is sustained for several 
hours, which extends the time window to demonstrate an effect of a therapeutic intervention, probably to a time 
point after initiation of endotoxin infusion. This is highly relevant, as in most patients with systemic inflamma-
tion, such as those suffering from sepsis, trauma or burns, there will be no opportunity for treatment before the 
inflammatory insult. Being able to demonstrate efficacy of an intervention administrated during inflammation 
would improve the clinical applicability. In addition, although still relatively short-lived, continuous endotoxin 
infusion may better represents the physiologic response of sustained immune triggering as observed in patients, 
including the emerging negative feedback mechanisms and development of endotoxin tolerance.
In conclusion, continuous infusion of endotoxin elicits a safe, reproducible, controlled, systemic inflammatory 
response in humans in vivo, which lasts for several hours. This model provides new options to study the innate 
immune response during continuous exposure to inflammatory stimuli. Furthermore, it offers a larger time win-
dow to evaluate immunomodulatory interventions following the onset of inflammation.
Methods
Study design. Data were obtained from the control arms of three randomized controlled studies, using pla-
cebo or endotoxin bolus administrations of 1 or 2 ng/kg, or a bolus administration of 1 ng/kg followed by con-
tinuous infusion of endotoxin at a dose of 1 ng/kg/h. Studies were performed after approval of the local ethics 
committee CMO Regio Arnhem-Nijmegen and are registered at ClinicalTrials.gov (NCT02642237 (December 
2015); NCT02085590 (March 2014); NCT02612480 (November 2015), respectively). All study procedures were 
in accordance with the declaration of Helsinki, including the latest revisions.
The purpose of this report is to characterize a novel human endotoxemia model aimed at eliciting systemic 
inflammation in a more clinically relevant manner and potentially providing more opportunities for pharmaco-
logic modulation. To provide an interpretational context, data of bolus injections of 1 and 2 ng/kg of the same 
endotoxin are also described. Because we did not include a group that received a bolus administration of 4 ng/
kg (the same cumulative dose as used in the continuous infusion group), it needs to be stressed that differences 
between the continuous infusion group and the bolus groups may either originate from a difference in infusion 
rate or a difference in cumulative dose.
Study protocols. Eligible subjects were healthy, non-smoking male subjects aged 18–35 years, with a normal 
physical examination, electrocardiography, and routine laboratory values at the screening visit. Exclusion criteria 
were pre-existent disease, febrile illness in the past four weeks and drug use. All subjects gave written informed 
consent to participate in the study. Before the experiment, subjects refrained from caffeine and alcohol for 24 h 
and from food and drinks for 12 h. Radial artery cannulation (Angiocath; Becton Dickinson, USA) facilitated 
blood pressure monitoring (Edward Lifesciences, Irvine, CA, USA) and blood withdrawal. A venous cannula 
was placed in an antebrachial vene for intravenous (i.v.) hydration and endotoxin administration. A three-lead 
www.nature.com/scientificreports/
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electrocardiogram registered heart rate. All haemodynamic data was recorded with an interval of 30 seconds 
using an in-house developed system from a Philips M50 monitor (Eindhoven, The Netherlands).
To prevent vasovagal responses subjects were prehydrated by infusion of 1.5 L glucose 2.5%/NaCl 0.45% in one 
hour28. Purified lipopolysaccharide (LPS, US Standard Escherichia coli O:113 endotoxin) was obtained from the 
Pharmaceutical Development Section of the National Institutes of Health (Bethesda, MD, USA). The lyophilized 
powder was reconstituted in 5 mL NaCl 0.9% for injection and vortex mixed for 20 min. An i.v. bolus of endotoxin 
was administered at a dose of 1 ng/kg or 2 ng/kg at 0 h. Continuous infusion was initiated after a bolus of 1 ng/
kg at 0 h, followed by a continuous infusion at 1 ng/kg/h for 3 h, resulting in a cumulative dose of 4 ng/kg shown 
to be safe in previous studies10–12. The placebo group received matched bolus volumes of vehicle (NaCl 0.9%) at 
0 h. Hydration was continued with 150 ml/h for 6 h, and 75 ml/h during the rest of the experiment. Every 30 min, 
temperature was measured using a tympanic thermometer (FirstTemp Genius 2; Covidien, Dublin, Ireland) and 
flu-like symptoms (headache, nausea, shivering, muscle and back pain) were scored on a six-point scale (0 = no 
symptoms, 5 = worst ever experienced), resulting in a total symptom score range of 0–25.
Cytokine analysis. Ethylenediaminetetraacetic-(EDTA) anticoagulated blood was collected at various time 
points, centrifuged (2000 g, 4 °C, 10 min) and plasma was stored at − 80 °C until analysis. As plasma concen-
trations may differ between assay manufacturers and batches, we re-analyzed concentrations of TNF-α , IL-6, 
CXCL8, IL-10, IL-1β , MIP-1α , MIP-1β and MCP-1 in all samplesbatchwise in one run using a simultaneous 
Luminex assay (R&D systems; Abingdon Science Park, UK). The lower detection limits were as follows; TNFα 
1,46 pg/mL, IL-1B 0,76 pg/mL, IL-6 1,76 pg/mL, CXCL8 1,41 pg/mL, IL-10 1.22 pg/mL, IFNy 0,66 pg/mL, MIP1a 
74,4 pg/mL, MIP1B 34 pg/mL, IL-1RA 26 pg/mL and MCP-1 13,2 pg/mL. Cross-reactivity was below 0.5% for all 
the cytokines, and the interassay variation was below 17%.
Leukocyte counts. Analysis of leukocyte counts were measured using routine methods also used for patient 
samples (flow cytometric analysis on a Sysmex XE-5000).
Statistical analysis. Distribution of data was tested for normality using Shapiro-Wilk test. As all data were 
normally distributed, they are presented as mean ± SEM. Total cytokine production is expressed as the area under 
the time curve (AUC) and group differences were analyzed using unpaired Students t-tests. Differences between 
groups in kinetics were analyzed using two-way analysis of variance (ANOVA) (group x time). Within group 
comparisons were made using one-way ANOVA followed by Bonferroni post-hoc tests. Hierarchical clustering 
analysis (HCA) was used to analyze coherence between cytokines. HCA is an unsupervised method to repre-
sent the relationships among variables with the length of the branch reflecting the degree of similarity. AUCs of 
cytokines from the endotoxemia groups were log-transformed and normalized, after which HCA was performed 
using Euclidean distances and an average clustering algorithm (CIMminer, Genomics and Bioinformatics group, 
National Cancer Institute, Bethesda, MD, USA). This analysis identified clusters of the cytokines (AUCs) and 
subjects. Exploratory factor analysis (EFA) was performed to identify groups of cytokine responses that correlate 
to such an extent that they could be summarized into one new variable (a factor). Thereby EFA is an unsuper-
vised method that identifies latent constructs (or factors) which can summarize data in factors that cannot be 
measured directly. These factors can be used to assess the coherence between cytokines and to assess the relation 
between clusters of cytokines with clinical parameters. EFA was performed on log-transformed cytokine AUCs 
using Oblimin rotation, as we assume that latent constructs of cytokine data may correlate and not be entirely 
independent. The scores of the subjects on the newly derived factors, which summarize all the cytokine data, 
were correlated with the AUC of symptoms, change in temperature, and change in heart rate using Pearson 
correlation analysis. Unless specified otherwise, statistical analyses were performed using Graphpad Prism ver-
sion 5.0 (Graphpad Software, San Diego, CA, USA) and SPSS for Windows 22.0 (SPSS Inc, Chicago, IL, USA). 
P-values < 0.05 were considered statistically significant.
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